What is APMD's market cap?

$641.11M, based on the Nov 2 close of $15.40.

How much of APMD is sold short?

1.8M shares, 10.1% of float, as of Oct 15, 2026.

What sector is APMD in?

Healthcare, in the Pharmaceuticals industry.

NASDAQ · APMDHealthcarePharmaceuticals

Apnimed, Inc. Common Stock (APMD)

$15.40−6.10%

Close Nov 2, 2026 · split-adjusted

Oct 30, 2026$16.40▼ 37.48% in range

Sep 11, 2026Low $16.40 · High $29.00Oct 30, 2026

What changed · written from our data

As of Nov 2, 2026

Apnimed closed at $15.40 on Nov 2, down 6.10%, within 0.0% of its lowest close since Sep 11. Volume of 530.9K shares was 1.38× its 20-day average (above normal).

Split-adjusted performance: -28.4% over one month.

Short interest was 1.8M shares at the Oct 15 settlement, up 2.2% from the prior report (10.1% of float, 3.9 days to cover).

Market cap$641.1M41.6M shares

Revenue · quarter——

Diluted EPS——

P/E · TTM—

Net margin—

Dividend yieldNone

Range since Sep 1115.40 – 29.00−46.9% from high

Volume530.9K1.38× 20-day avg

Volatility · 60d—Annualised

Short % of float10.1%3.9 days to cover

Net cash—

Next earnings—Not scheduled

Split-adjusted performance

1W −18.7%1M −28.4%3M —6M —YTD —1Y —3Y —5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum—

Revenue growth—

Net margin—

Value (low P/E)—

Size66

Industry medians: 6-month return −25.1%, revenue growth +6.4%, net margin −36.2%, P/E 15.8×.

Short interest

Details →

Shares short1.8M+2.2% vs prior

Days to cover3.9Settled Oct 15

% of float10.1%

Short vol. 10d59.4%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
APMDApnimed	$15.40	−6.10%	—	—	—	—	$641.1M
LXRXLexicon Pharmaceuticals	$1.44	+1.41%	−10.0%	−97.6%	−4591.8%	—	$640.7M	Compare
DSGNDesign Therapeutics	$10.15	−4.96%	−22.9%	—	—	—	$635.2M	Compare
NVCTNuvectis Pharma	$19.18	+3.79%	+115.7%	—	—	—	$626.1M	Compare
AVBPArriVent BioPharma	$13.35	−10.22%	−56.1%	—	—	—	$658.3M	Compare
OLMAOlema Pharmaceuticals	$7.07	+1.00%	−51.7%	—	—	—	$618.6M	Compare
IMMXImmix Biopharma	$7.26	−5.47%	−23.4%	—	—	—	$601.9M	Compare
ZVRAZevra Therapeutics	$10.10	−1.75%	+0.5%	+53.3%	21.2%	10.4	$599.8M	Compare
SGMTSagimet Biosciences Inc. Series A	$9.69	−2.32%	+22.7%	—	—	—	$687.1M	Compare

News about Apnimed

All news →

Apnimed Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional SharesGlobeNewswire Inc. · Aug 3, 2026▲ Positive

Quick answers

What does Apnimed do?: Apnimed Inc is a late clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep related breathing diseases. The company's flagship product candidate, AD109, or Oxnimbi, is an investigational, fixed-dose oral combination of a novel anti-muscarinic and selective norepinephrine reuptake inhibitor for the treatment of obstructive sleep apnea (OSA).
What is APMD's market cap?: $641.11M, based on the Nov 2 close of $15.40.
How much of APMD is sold short?: 1.8M shares, 10.1% of float, as of Oct 15, 2026.
What sector is APMD in?: Healthcare, in the Pharmaceuticals industry.

About Apnimed

Apnimed Inc is a late clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep related breathing diseases. The company's flagship product candidate, AD109, or Oxnimbi, is an investigational, fixed-dose oral combination of a novel anti-muscarinic and selective norepinephrine reuptake inhibitor for the treatment of obstructive sleep apnea (OSA).

HQ: Cambridge, MAListed Jul 31, 2026apnimed.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology